| Eskens FA, Mom CH, Planting AS, et al.
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. [JOURNAL ARTICLE]
Br J Cancer 2007 Nov 20.
Abstract | Full Citation | Find Related Articles | | Kieran MW, Packer RJ, Onar A, et al.
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. [Journal Article, Research Support, N.I.H., Extramural]
J Clin Oncol 2007 Jul 20; 25(21):3137-43.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Diemert DJ
Prevention and Self-Treatment of Traveler's Diarrhea. [Journal Article]
Clin Microbiol Rev 2006 Jul; 19(3):583-94.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Karthaus M, Ballo H, Abenhardt W, et al.
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
Oncology 2005; 68(4-6):326-32.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Tobin PJ, Beale P, Noney L, et al.
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. [Clinical Trial, Journal Article]
Cancer Chemother Pharmacol 2006 Feb; 57(3):309-16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Van Ummersen L, Binger K, Volkman J, et al.
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
Clin Cancer Res 2004 Nov 15; 10(22):7450-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Michael M, Brittain M, Nagai J, et al.
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2004 Nov 1; 22(21):4410-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Jodrell DI, Evans TR, Steward W, et al.
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
Eur J Cancer 2004 Aug; 40(12):1872-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Benson AB, Ajani JA, Catalano RB, et al.
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. [Guideline, Journal Article, Practice Guideline]
J Clin Oncol 2004 Jul 15; 22(14):2918-26.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Rosenoff S
Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. [Case Reports, Journal Article]
Support Care Cancer 2004 Aug; 12(8):561-70.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
